Submission of Matters to a Vote of Security Holders – Form 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Singular Genomics Systems, Inc.

(Exact name of registrant as specified in its charter)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

On May 25, 2023, Singular Genomics Systems, Inc. (the "Company") held its 2023 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on the following proposals, which are described in more detail in the Company's Definitive Proxy Statement on Schedule 14A that was filed with the U.S. Securities and Exchange Commission on April 13, 2023 (the "Proxy Statement"):

Only stockholders of record at the close of business on March 31, 2023 (the "Record Date") were entitled to vote at the Annual Meeting. At the close of business on the Record Date, 72,388,932 shares of the Company's common stock were issued and outstanding, of which 55,661,943 shares of common stock were present at the Annual Meeting, either in attendance via the live webcast or represented by proxy, which total constituted a quorum of the issued and outstanding shares.

Each of the proposals voted on at the Annual Meeting was approved by the Company's stockholders. The final voting results with respect to each of the proposals are set forth below.

Proposal 1: Election of Directors

Proposal 2: Ratification of Appointment of Independent Registered Accounting Firm

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Attachments

• Original Link
• Original Document
• Permalink

Disclaimer

Singular Genomics Systems Inc. published this content on 26 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 May 2023 10:09:24 UTC.